Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell ...

While first-line EGFR inhibitors have revolutionized the treatment of mutant lung cancer, the inevitable development of therapeutic resistance remains a primary clinical hurdle. I ...

Zegfrovy (sunvozertinib) received accelerated FDA approval for NSCLC patients with EGFR exon 20 insertion mutations post-platinum-based chemotherapy progression. The Oncomine Dx Express Test was ...

To conclude our interview with Joshua K. Sabari, MD, which focused on the approval of amivantamab plus lazertinib in the first line, he looks ahead to potential uses that could help to overcome ...

Detailed price information for Beone Medicines Ltd (ONC-Q) from The Globe and Mail including charting and trades.

Detailed price information for Black Diamond Therapeutics Inc (BDTX-Q) from The Globe and Mail including charting and trades.

Dr. Shannon Westin and her guests, Dr. Judy Garber and Dr. Geoffrey Oxnard, discuss the paper "Germline EGFR Mutations and Familial Lung Cancer" recently published in the JCO. The authors have no ...

Combining TRT with EGFR-TKIs significantly improves PFS and OS in EGFR-mutated oligo-organ metastatic NSCLC patients compared to EGFR-TKIs alone. The study suggests personalized treatment approaches, ...

Adding the VEGF inhibitor ramucirumab (Cyramza) to the EGFR inhibitor osimertinib (Tagrisso) slowed progression of untreated EGFR-positive non-small cell lung cancer (NSCLC) by 9 months compared with ...

Could a daily pill after chemoradiation keep lung cancer from returning? The News On 6 weekend team provides a comprehensive look at updated news events, a detailed and up-to-the-minute weather ...